- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/30 - Oxygen atoms
Patent holdings for IPC class C07D 213/30
Total number of patents in this class: 636
10-year publication summary
|
59
|
52
|
40
|
44
|
37
|
32
|
33
|
29
|
20
|
25
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4820 |
12 |
| Abbvie Inc. | 1815 |
12 |
| Unigen, Inc. | 113 |
12 |
| Sumitomo Chemical Company, Limited | 9109 |
11 |
| Global Blood Therapeutics, Inc. | 183 |
8 |
| Purdue Pharma L.P. | 495 |
8 |
| Mycovia Pharmaceuticals, Inc. | 40 |
8 |
| Novartis AG | 10623 |
7 |
| The Regents of the University of California | 20289 |
6 |
| AstraZeneca AB | 2858 |
6 |
| Chiesi Farmaceutici S.p.A. | 973 |
6 |
| JNC Corporation | 1508 |
6 |
| Calico Life Sciences LLC | 104 |
6 |
| Merck Sharp & Dohme LLC | 3737 |
6 |
| Allergan, Inc. | 2314 |
5 |
| Galderma Research & Development | 389 |
5 |
| JNC Petrochemical Corporation | 327 |
5 |
| F. Hoffmann-La Roche AG | 7933 |
4 |
| BASF SE | 21087 |
4 |
| LG Chem, Ltd. | 17679 |
4 |
| Other owners | 495 |